The researchers discovered that BPC-157 achieves this by increasing the number of a specific type of receiver (called VEGFR2) on the surface of these cells
For Clinicians: Maintain evidence-based practice, avoid hype
Framing FDA approval as Not Yet implies a conventional NDA pathway, but that is unlikely for a non-patentable peptide without a sponsor funding Phase IIII trials
This reaction is severe and potentially life-threatening, including symptoms like unease, tingling, dizziness, itching, hives, swelling, difficulty breathing, and fainting
PMID: 16583442
Foundational Research in Diet-Induced Obese Mice The frequently repeated weight and fat findings originate from a short mouse proof-of-concept study